Decision delayed over NH state Rx data

Share this article:
A federal judge took an unusual step last month of asking lawyers to critique a draft of his factual findings before ruling in IMS Health and Verispan’s high-profile challenge to New Hampshire’s state law limiting drug company access to doctors’ prescribing habits.

The Associated Press reported that Judge Paul Barbadoro asked lawyers for both sides in the case to meet with him to review his proposed factual findings, apparently in hopes to address some objections before ruling and providing the 1st US Circuit Court of Appeals in Boston with a clear decision.

Barbadoro cautioned that no one should try to predict his ruling from the draft, but some
of his comments showed his skepticism about key arguments—including the state’s contention that detailing drives up drug prices.

“If reasonable medical people disagree,” about the merits of various drugs for the same medical condition, “you have a stronger argument that speech restrictions are dangerous,” Barbadoro said. He expects to rule this month.  

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...